Cardiology Masterclass / Symposium 

LDL-C Management: Should it begin in the cath lab?

Highlights from a satellite symposium at EuroPCR 2026

Dr. Brian Bergmark 

Dr. Brian Bergmark 
Prof. Gilles Montalescot

Prof. Gilles Montalescot
Dr. Campbell Rogers

Dr. Campbell Rogers
Publication Date

Jun 2026

info Summary and next episodes

In these short videos, experts Prof. Montalescot, Dr. Bergmark, and Dr. Rogers share key insights from their presentations at the satellite symposium ‘LDL-C Management: Should it begin in the cath lab?’ at EuroPCR 2026, chaired by Prof. Montalescot, and sponsored by Amgen. 

 

Topics include:

  • Results from VESALIUS-CV and the role of evolocumab in patients with prior percutaneous coronary intervention (PCI) and no prior myocardial infarction (MI) 
  • Low-density lipoprotein cholesterol (LDL-C) management during acute coronary syndrome (ACS) with potential insights from AMUNDSEN and EVOLVE-MI 
  • Imaging in the age of AI and its impact on earlier treatment 

 

 

Clinical takeaways

  • Patients with ACS and MI may benefit from early implementation of PCSK9 inhibitors

  • A sub-analysis of the VESALIUS-CV study showed that patients with prior PCI but no prior MI or stroke had substantial reduction in LDL-C levels and risk of cardiovascular events with evolocumab treatment

  • Initial observations of the disease burden may guide and monitor response to therapy to optimise management of coronary disease and high LDL-C

  • Understand the role of evolocumab in patients with prior percutaneous coronary intervention and no prior MI, with a focus on results from VESALIUS-CV
  • Evaluate the potential of AMUNDSEN and EVOLVE-MI for the management of LDL-C during Acute Coronary Syndrome 
  • Appreciate how AI-enabled observations of disease burden may guide and monitor response to therapy to optimise management of coronary disease and high LDL-C

Dr. Rogers brings a wealth of experience to HeartFlow, where he serves as the Executive Vice President and Chief Medical Officer. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, he was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. He served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases, and was the recipient of research grant awards from the NIH and AHA. He received his A.B. from Harvard College and his M.D. from Harvard Medical School.

In these short videos, experts Prof. Montalescot, Dr. Bergmark, and Dr. Rogers share key insights from their presentations at the satellite symposium ‘LDL-C Management: Should it begin in the cath lab?’ at EuroPCR 2026, chaired by Prof. Montalescot, and sponsored by Amgen. 

 

Topics include:

  • Results from VESALIUS-CV and the role of evolocumab in patients with prior percutaneous coronary intervention (PCI) and no prior myocardial infarction (MI) 
  • Low-density lipoprotein cholesterol (LDL-C) management during acute coronary syndrome (ACS) with potential insights from AMUNDSEN and EVOLVE-MI 
  • Imaging in the age of AI and its impact on earlier treatment 

 

 

Clinical takeaways

  • Patients with ACS and MI may benefit from early implementation of PCSK9 inhibitors

  • A sub-analysis of the VESALIUS-CV study showed that patients with prior PCI but no prior MI or stroke had substantial reduction in LDL-C levels and risk of cardiovascular events with evolocumab treatment

  • Initial observations of the disease burden may guide and monitor response to therapy to optimise management of coronary disease and high LDL-C

  • Understand the role of evolocumab in patients with prior percutaneous coronary intervention and no prior MI, with a focus on results from VESALIUS-CV
  • Evaluate the potential of AMUNDSEN and EVOLVE-MI for the management of LDL-C during Acute Coronary Syndrome 
  • Appreciate how AI-enabled observations of disease burden may guide and monitor response to therapy to optimise management of coronary disease and high LDL-C

Gilles Montalescot is Professor of Cardiology at the Pitié Salpêtrière Hospital in Paris, France, where he heads the Department of Cardiology at the Institute of Cardiology. He is a practicing Interventional Cardiologist and has extensive experience in basic and clinical research. He has been the director of the INSERM research Unit UMRS_1166 on Thrombosis for 10 years.

 

Dr Montalescot has been an investigator for many of the new drugs developed in the past twenty years as well as for many of the new interventional technologies. Dr Montalescot is a senior scientist and has been the lead investigator of many national or international randomized trials including ADMIRAL, ARMADA, ALBION, STEEPLE, ARCHIPELAGO, ABOARD, ACAPULCO, ATOLL, ARCTIC, ANTARCTIC, ACCOAST, ATLANTIC, AEGEAN, AMERICA, ALBATROS, and the ongoing ATLANTIS, ALPHEUS, ARAMIS, ADRIFT trials.

 

Dr Montalescot is the Chairman of the ACTION study group, an Academic Research Organization based at Pitié Salpêtrière Hospital in Paris. He has served on several task force committees on antithrombotic drugs and acute coronary syndromes and is the current Chairman of the Stable Coronary Artery disease guidelines of the European Society of Cardiology.

 

Dr Montalescot has received several awards in his country including the J. Valade Prize from the Fondation de France and the J.Escalle award from the National Academy of Medicine. He is a member of several editorial boards and has published over 600 peer reviewed original articles in journals such as the NEJM, JAMA, Lancet. Internationally, Dr Montalescot has also been an invited speaker at plenary sessions of major congresses such as the European Society of Cardiology, the American College of Cardiology ,and the American Heart Association.

Prof. Gilles Montalescot has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Abbott, Amgen, AstraZeneca, Boehringer-Ingelheim, Celecor Therapeutics, Cell Prothera, Corflow, GSK, Medpace, MSD, Novo Nordisk, Pfizer, Sanofi, SMT, Viatris.

In these short videos, experts Prof. Montalescot, Dr. Bergmark, and Dr. Rogers share key insights from their presentations at the satellite symposium ‘LDL-C Management: Should it begin in the cath lab?’ at EuroPCR 2026, chaired by Prof. Montalescot, and sponsored by Amgen. 

 

Topics include:

  • Results from VESALIUS-CV and the role of evolocumab in patients with prior percutaneous coronary intervention (PCI) and no prior myocardial infarction (MI) 
  • Low-density lipoprotein cholesterol (LDL-C) management during acute coronary syndrome (ACS) with potential insights from AMUNDSEN and EVOLVE-MI   
  • Imaging in the age of AI and its impact on earlier treatment 

 

 

Clinical takeaways

  • Patients with ACS and MI may benefit from early implementation of PCSK9 inhibitors

  • A sub-analysis of the VESALIUS-CV study showed that patients with prior PCI but no prior MI or stroke had substantial reduction in LDL-C levels and risk of cardiovascular events with evolocumab treatment

  • Initial observations of the disease burden may guide and monitor response to therapy to optimise management of coronary disease and high LDL-C

  • Understand the role of evolocumab in patients with prior percutaneous coronary intervention and no prior MI, with a focus on results from VESALIUS-CV
  • Evaluate the potential of AMUNDSEN and EVOLVE-MI for the management of LDL-C during Acute Coronary Syndrome 
  • Appreciate how AI-enabled observations of disease burden may guide and monitor response to therapy to optimise management of coronary disease and high LDL-C

Dr. Rogers brings a wealth of experience to HeartFlow, where he serves as the Executive Vice President and Chief Medical Officer. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, he was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. He served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases, and was the recipient of research grant awards from the NIH and AHA. He received his A.B. from Harvard College and his M.D. from Harvard Medical School.

Programme summary
  • clock Duration 2 MIN
  • clock Language(s) flag
Watch the video now
Share this programme
x-twitter
Brought to you by COR2ED Medical Affairs in collaboration with Amgen. SC-ELMAC-AMG145-00302
Supporter Acknowledgement
Brought to you by COR2ED Medical Affairs in collaboration with Amgen. SC-ELMAC-AMG145-00302
I agree that this programme:

Was valuable to me

1/3
Programme summary
  • clock Duration 2 MIN
  • clock Language(s) flag
Watch the video now
Share this programme
x-twitter
Brought to you by COR2ED Medical Affairs in collaboration with Amgen. SC-ELMAC-AMG145-00302
Supporter Acknowledgement
Brought to you by COR2ED Medical Affairs in collaboration with Amgen. SC-ELMAC-AMG145-00302
I agree that this programme:

Was valuable to me

1/3
Programme summary
  • clock Duration 2 MIN
  • clock Language(s) flag
Watch the video now
Share this programme
x-twitter
Brought to you by COR2ED Medical Affairs in collaboration with Amgen. SC-ELMAC-AMG145-00302
Supporter Acknowledgement
Brought to you by COR2ED Medical Affairs in collaboration with Amgen. SC-ELMAC-AMG145-00302
I agree that this programme:

Was valuable to me

1/3

Other programmes of interest

animated-video Animated Video

Episode

4

of 5

episode
Cardiology 
Warnsignale eines Herzinfarkts, die jeder kennen sollt

Herzinfarkt-Symptome erkennen und schnell handeln

Experts
Prof. Gilles Montalescot, Prof. Marco Valgimigli
Endorsed by
Parole & Réaction
Ticino Cuore Foundation 
  • download Downloadable
    Resources
  • clock 3 MIN
  • calendar Mar 2026
  • Non-accredited Independent Medical Education
CORONARY CONNECT
Dieses Bildungsprogramm wird durch einen Unabhängigen Bildungszuschuss von Viatris unterstützt. 
animated-video Animated Video

Episode

2

of 5

episode
Cardiology 
Signes avant-coureurs de la crise cardiaque que tout le monde doit connaître

Reconnaître les symptômes d’une crise cardiaque et agir vite

Experts
Prof. Gilles Montalescot, Prof. Marco Valgimigli
Endorsed by
Parole & Réaction
Ticino Cuore Foundation 
  • download Downloadable
    Resources
  • clock 3 MIN
  • calendar Mar 2026
  • Non-accredited Independent Medical Education
CORONARY CONNECT
Educational programme supported by an Independent Educational Grant from Viatris
animated-video Animated Video

Episode

5

of 5

episode
Cardiology 
Знаци упозорења на срчани удар које би свако требало да зна

Препознавање симптома срчаног удара и брза реакција

Experts
Prof. Gilles Montalescot, Prof. Marco Valgimigli
Endorsed by
Parole & Réaction
Ticino Cuore Foundation 
  • download Downloadable
    Resources
  • clock 3 MIN
  • calendar Mar 2026
  • Non-accredited Independent Medical Education
CORONARY CONNECT
Овај едукативни програм подржан је кроз Независни образовни грант компаније Виатрис. 
animated-video Animated Video

Episode

3

of 5

episode
Cardiology 
Segnali di avvertimento di infarto che tutti dovrebbero conoscere

Riconoscere i sintomi di infarto e agire rapidamente

Experts
Prof. Gilles Montalescot, Prof. Marco Valgimigli
Endorsed by
Parole & Réaction
Ticino Cuore Foundation 
  • download Downloadable
    Resources
  • clock 3 MIN
  • calendar Mar 2026
  • Non-accredited Independent Medical Education
CORONARY CONNECT
Questo programma educativo è sostenuto da un Supporto Educazionale Indipendente di Viatris.
animated-video Animated Video

Episode

1

of 5

episode
Cardiology 
Heart attack warning signs everyone should know

Recognising heart attack symptoms and acting fast

Experts
Prof. Gilles Montalescot, Prof. Marco Valgimigli
Endorsed by
Parole & Réaction
Ticino Cuore Foundation 
  • download Downloadable
    Resources
  • clock 3 MIN
  • calendar Jan 2026
  • Non-accredited Independent Medical Education
CORONARY CONNECT
Educational programme supported by an Independent Educational Grant from Viatris
conference-update Conference update
Cardiology 
Lipid management highlights from AHA 2025

Expert insights on the latest clinical trial data in lipid management

Experts
Dr Robert P. Giugliano, Prof. Ulrich Laufs
Endorsed by
Ticino Cuore Foundation 
Parole & Réaction
  • clock 6 MIN
  • calendar Nov 2025
  • Non-accredited Independent Medical Education
CORONARY CONNECT
Educational programme supported by an Independent Educational Grant from Amgen.
Explore all programmes